BioCryst Pharmaceuticals, Inc. (BCRX) |
4.16 -0.05 (-1.19%) 04-25 16:00 |
Open: | 4.13 |
High: | 4.17 |
Low: | 4.03 |
Volume: | 2,635,571 |
Market Cap: | 858(M) |
PE Ratio: | -3.53 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 5.87 |
Resistance 1: | 5.17 |
Pivot price: | 4.58 |
Support 1: | 4.03 |
Support 2: | 3.35 |
52w High: | 9.07 |
52w Low: | 4.03 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
EPS | -1.180 |
Book Value | -2.210 |
PEG Ratio | -0.16 |
Gross Profit | 0.000 |
Profit Margin (%) | -68.36 |
Operating Margin (%) | -40.41 |
Return on Assets (ttm) | -11.6 |
Return on Equity (ttm) | 0.0 |
Tue, 23 Apr 2024
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Mon, 22 Apr 2024
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing - Yahoo Finance
Fri, 19 Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 52-Week Low at $4.44 - MarketBeat
Wed, 03 Apr 2024
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shift From Loss To Profit - Simply Wall St
Tue, 05 Mar 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX investor three-year losses grow to 54% as the stock sheds US$74m this ... - Simply Wall St
Wed, 28 Feb 2024
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |